NCT05849298 2026-03-03
PSMACare
Novartis
Phase 2 Active not recruiting
Clinical Trials
10 trialsActive not recruiting × 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid × Clear all
NCT03173924 2026-01-21
18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT03976843 2025-12-18
Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT05470699 2025-12-17
RefleXion PET/CT Imaging Performance in Patients With Prostate Cancer
City of Hope Medical Center
Phase NA Active not recruiting
NCT04687969 2025-09-25
Multimodal Machine Learning Characterization of Solid Tumors
Massachusetts General Hospital
Active not recruiting
NCT06074510 2025-09-11
MIRROR
Lantheus Medical Imaging
Phase 4 Active not recruiting
NCT03860987 2025-09-08
Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT05095519 2025-07-16
HepaSMART
Peter MacCallum Cancer Centre, Australia
Phase 2 Active not recruiting
NCT03392181 2025-05-23
PET/MRI for the Staging of Newly Diagnosed Prostate Cancer
Northwestern University
Phase EARLY_PHASE1 Active not recruiting
NCT03471650 2025-03-10
Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting